Market intelligence, trend analysis and forecasts for the Pharma and Healthcare industries across the regions

Industry / Canada

Rx&D Pledge In R&D Spending Not Met

July 2012 | Industry Trend Analysis

BMI View: Canada's policy of supporting high drug prices in order to support national R&D should be reviewed, as the R&D spending to domestic revenue ratio has declined below the level seen in the US and Europe, as well as the global industry average. BMI believes the Canadian government should keep healthcare costs efficient as well as encouraging pharmaceutical companies to continue to invest in R&D by refining its drug price policy, regulatory processes and its national biomedical research capabilities.

To read the full article, please choose one of the following options:

Subcribers please log in